Onyx Kyprolis Launch Strategy Includes Speedy Delivery, Premium Price

Onyx is pricing new myeloma drug carfilzomib at $9,950 per cycle, 65% higher than Takeda/Millennium’s pioneering proteasome inhibitor Velcade. Launch plans include financial assistance for providers, comprehensive patient assistance program and transition for expanded access patients to commercial drug.

More from Approvals

More from Product Reviews